Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease

NCT01468168 is registered in ClinicalTrials.gov with Santen Inc. as lead sponsor.

NCT NCT01468168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01468168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Lead sponsor
Santen Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
November 30, 2012
Enrollment
183 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease